StockData

Compugen vs Monte Rosa Therapeutics

CGEN and GLUE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CGEN and GLUE compare

Compugen grew revenue faster over the last twelve months (161% versus −83.9% for Monte Rosa Therapeutics).

Compugen keeps more of each dollar of sales as profit, with a net margin of 48.6% compared with −561% at Monte Rosa Therapeutics.

Compugen scores higher on the StockData Score (12 against 7 for Monte Rosa Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCGENGLUE
Size and price
Market cap–$781M
Share price$2.04$9.16
Change, 1 year23.6%−36.0%
Change, 5 years−55.1%−55.4%
Beta (5Y)1.542.01
Employees2150
StockData Score
Total score12 (better)7
Valuation score01 (better)
Growth score3 (better)0
Performance score4 (better)1
Health score55
Dividend score00
Valuation
P/S–27.2×
P/B–1.6×
FCF yield–−4.1%
Fair value–$6.49
Margin of safety–−41.2%
Growth
Revenue growth (TTM)161% (better)−83.9%
Revenue growth, 5Y average105%–
Net income growth (TTM)–−767%
EPS growth (TTM)–−707%
Profitability
Gross margin87.3%–
Operating margin43.1% (better)−633%
Net margin48.6% (better)−561%
FCF margin43.1% (better)−112%
Return on equity50.9% (better)−42.7%
Return on invested capital117%–
Financial health
Debt / equity0.000.00
Current ratio5.7210.58 (better)
Altman Z-score–1.32
Piotroski F-score7 (better)5
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–109%
Held by insiders0.43%11.5%
Insider net buying, 12 months−$126K (better)−$4.1M
Superinvestors holding–1
Short interest, % of float2.7%27.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.